^18F-FDOPA PET/CT is the preferred imaging modality for localization of pheochromocytoma.
Rationale Based on Guidelines and Evidence
For sporadic, non-metastatic pheochromocytomas, ^18F-FDOPA PET/CT demonstrates superior or equivalent performance to ^68Ga-DOTATATE PET/CT 1. The 2012 EANM guidelines specifically state that for apparently sporadic non-metastatic pheochromocytomas, there is no clear advantage of using PET tracers over ^123I-MIBG scintigraphy, but when PET is chosen, ^18F-FDOPA shows higher sensitivity than ^123I-MIBG and is more specific than ^18F-FDG 1.
Performance Characteristics
^18F-FDOPA PET/CT:
- Sensitivity: 97% (95% CI: 91-99%) for initial pheochromocytoma diagnosis 2
- Specificity: 94% (95% CI: 86-98%) 2
- Diagnostic accuracy: 98.9% for pheochromocytoma patients 2
- Area under curve: 0.99 2
^68Ga-DOTATATE PET/CT:
- Diagnostic accuracy: 86.9% for pheochromocytoma 2
- May miss small adrenal pheochromocytomas (documented cases of millimeter-sized lesions missed) 3
- Patient-based sensitivity: 93% but lesion-based sensitivity lower for pheochromocytomas specifically 3
Clinical Algorithm for Imaging Selection
1. For adrenal pheochromocytoma (sporadic or suspected):
- First-line: ^18F-FDOPA PET/CT 1, 2
- Alternative: ^123I-MIBG if PET unavailable 1
- Avoid: ^68Ga-DOTATATE may be inferior for adrenal lesions 3
2. For head/neck paragangliomas:
- First-line: ^68Ga-DOTATATE PET/CT (sensitivity approaching 100% for these locations) 1
- ^18F-FDOPA is second-line for this specific location 1
3. For metastatic disease:
- If SDHB-related: ^18F-FDG PET is imaging of choice 4, 1
- If non-SDHB or unknown genetics: ^18F-FDOPA PET/CT 1, 5
- ^68Ga-DOTATATE shows better performance for bone metastases but worse for liver metastases 6, 5
Key Distinguishing Features
^18F-FDOPA advantages for pheochromocytoma:
- No physiologic adrenal uptake (unlike ^123I-MIBG which shows uptake in 50% of normal adrenals) 4, 1
- Superior detection of small adrenal lesions 3
- Better overall sensitivity and specificity for pheochromocytoma specifically 2, 5
- More specific than ^18F-FDG 1
^68Ga-DOTATATE limitations for pheochromocytoma:
- Documented cases of missing small pheochromocytomas (millimeter-sized) 3
- One study showed it missed a large recurrent pheochromocytoma 3
- Lower diagnostic accuracy (86.9% vs 98.9%) 2
- May have false positives (e.g., fibrous dysplasia) 3
Important Caveats
- The 2014 Endocrine Society guidelines 4 predate widespread ^68Ga-DOTATATE availability and primarily discuss ^18F-FDOPA, ^18F-FDG, and somatostatin receptor imaging with ^111In-pentetreotide
- Most recent meta-analysis (2025) confirms ^18F-FDOPA superiority for pheochromocytoma 2
- ^68Ga-DOTATATE excels for head/neck paragangliomas and bone metastases but not for primary adrenal pheochromocytomas 6, 3, 7
- The FDA-approved ^68Ga-DOTATATE (NETSPOT) 8 is indicated for somatostatin receptor-positive neuroendocrine tumors but clinical trial data focused on NETs, not specifically pheochromocytomas
For genetic syndromes: MEN2-related pheochromocytomas specifically benefit from ^18F-FDOPA due to absence of normal adrenal uptake 1. VHL and NF1-related tumors also favor ^18F-FDOPA 1.